WEALTH ENHANCEMENT ADVISORY SERVICES, LLC
Position in FATE — Fate Therapeutics Inc
CIK 1632972
PLYMOUTH, MN
Position in FATE
as of Jun 30, 2026
· filed Jul 15, 2026
Position Value
$244,298
+$158,509 QoQ
Shares Held
90,481
+26.6% QoQ
Ownership
0.078%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#2
of 7 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 2.735380908699064.ToString("F0")%
Shared 0.ToString("F0")%
None 97.26461909130094.ToString("F0")%
Common Shares in FATE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026WEALTH ENHANCEMENT ADVISORY SERVICES, LLC holds $166,117,226 across 147 Biotechnology names. FATE ranks #77 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
45,889 | $22,794,442 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
33,880 | $21,125,535 | |
| 3 | INCY |
Incyte Corp
|
151,505 | $17,174,606 | |
| 4 | EXEL |
Exelixis, Inc.
|
207,728 | $11,302,480 | |
| 5 | RPRX |
Royalty Pharma plc
|
179,888 | $10,086,320 | |
| 6 | CORT |
Corcept Therapeutics Inc
|
76,278 | $6,632,372 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
70,797 | $5,541,281 | |
| 8 | AXSM |
Axsome Therapeutics, Inc.
|
19,919 | $4,875,573 |
All Filings in FATE
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $244,298 | 90,481 | Shares | Sole | 2026-07-15 | |
| 2026-03-31 | $85,789 | 71,491 | Shares | Sole | 2026-04-08 | |
| 2025-12-31 | $34,226 | 34,925 | Shares | Sole | 2026-01-08 | |
| 2025-09-30 | $48,816 | 38,743 | Shares | Sole | 2025-10-29 | |
| 2025-06-30 | $39,588 | 35,347 | Shares | Sole | 2025-07-10 | |
| 2025-03-31 | $23,628 | 29,909 | Shares | Sole | 2025-04-16 | |
| No filing history on record for this holder in this stock. | ||||||